Low dose naltrexone (LDN) against cancer
Cancer core and also “NON-STAGE IV / Add-On treatment
What is LDN?
Prescribed ‘off-label’, Naltrexone (generic name) is a prescription opioid antagonist drug given at unconventionally low doses showing great promise in treating autoimmune diseases (including central nervous system disorders, COPD), cancer, HIV/AIDS and more.
- LDN is believed to work against diseases by improving immune function. By marginally blocking your opioid receptors for a few hours in the middle of the night, which is believed to up-regulate vital elements of your immune system by increasing your body’s production of metenkephalin and endorphins (your natural opioids), hence improving immune function.
For more information on LDN:
LDN used against cancers
LDN is used:
As a preventive treatment against cancer
To prevent a recurrence of cancer
To treat cancer – LDN has been shown in many cases to work with virtually incurable cancers such as neuroblastoma, multiple myeloma, and pancreatic cancer.
Research on neuropeptide receptors expressed by various human tumors has found opioid receptors in many types of cancer:
- Brain tumors (both astrocytoma and glioblastoma)
- Breast cancer
- Endometrial cancer
- Head and neck squamous cell carcinoma
- Myeloid leukemia
- Lung cancer (both small cell and non-small cell)
- Neuroblastoma
- Others…
LDN effects against cancer
Increased endorphin production and other related factors linked to anti-cancer mechanisms – Dr. Bernard Bihari, who first discovered LDN as a therapeutic agent for AIDS, in 1985, believes LDNs anti-cancer mechanism is likely due to an increase in:
▲ Increased endorphins (morphine-like substances originating from inside the body)
▲ Number and density of opiate receptors on the tumor cell membranes – making them more responsive to the growth-inhibiting effects of the already present levels of endorphins, which in turn induces apoptosis (cell death) in the cancer cells
▲ The absolute numbers of circulating cytotoxic T-cells and natural killer cells – as well as killer cell activity
Dr. Bihari reports promising results in treating 450+ cancer patients with LDN –, including cancers of the bladder, breast, liver, lung, lymph nodes, colon, and rectum. According to Dr. Bihari, close to a quarter of his patients had at least a 75% reduction in tumor size, and nearly 60% of his patients demonstrated disease stability.
Dr Ian Zagon has shown in one study that LDN can stop breast cancer cells growing in multiple resistant breast cancer –by a mechanism that acts on the ‘p21 cyclin-dependent inhibitory kinase pathway, present in many solid tumors and a large proportion of breast cancers
http://www.sciencedaily.com/releases/2013/08/130810063639.htm
http://ldnresearchtrust.org/sites/default/files/LDN%20Information%20Pack(1).pdf
The Berkson Method is a cancer therapy that combines LDN and Alpha Lipoic Acid
http://www.anticancer.org.uk/2011/10/q-with-dr-burt-berkson-low-dose.html
